Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)
Related Posts
Riccardi V, Viscomi CF, Sandri M, D'Alessandro A, Dzieciatkowska M, Stephenson D, Federti E, Hermann A, Salviati L, Siciliano A, Andolfo I, Alper SL, Ceolan[...]
Chotard M, Wang X, Zheng X, Kaye TG, Grosmougin M, Barlow L, Kundrát M, Dececchi TA, Habib MB, Zariwala J, Hartman S, Xu X, Pittman[...]
Klein R, Julian KA, Alba-Nguyen S, Ufere NN, Jassal SK, Simon W, Millard A, Uthlaut B, Koch J, Snyder ED, Volerman A, Thompson V, Kumar[...]